Results show that various classes of antidepressants exert improving effects on cognitive function across several cognitive domains .
Specifically , studies suggest that SSRIs , the SSRE tianeptine , the SNRI duloxetine , vortioxetine and other antidepressants such as bupropion and moclobemide may exert certain improving effects on cognitive function in depression , such as in learning and memory and executive function .
The few non-pharmacological studies conducted employing cognitive orientated treatments and cognitive remediation therapy show promising results for the improvement of cognitive impairment in depression .
Cognitive dysfunction is of clinical significance and exerts longst and ing implication on patients ׳ function .
Pharmacological and non-pharmacological treatments of cognitive dysfunction are emerging .
This review evaluates pharmacological and non-pharmacological treatments of cognitive impairment primarily in the domains of memory , attention , processing speed and executive function in clinical depression .
Effects of S-adenosylmethionine augmentation of serotonin-reuptake inhibitor antidepressants on cognitive symptoms of major depressive disorder.
BACKGROUND Major depressive disorder ( MDD ) is often accompanied by significant cognitive impairment , and there are limited interventions specific to this particular symptom . S-adenosyl methionine ( SAMe ) , a naturally occurring molecule which serves as a major methyl-donor in human cellular metabolism , is required for the synthesis and maintenance of several neurotransmitters that have been implicated in the pathophysiology and treatment of cognitive dysfunction in MDD . METHODS This study is a secondary analysis of a clinical trial involving the use of adjunctive SAMe for MDD . Forty-six serotonin-reuptake inhibitor ( SRI ) non-responders with MDD enrolled in a 6-week , double-blind , r and omized trial of adjunctive oral SAMe  were administered the self-rated cognitive and physical symptoms question naire ( CPFQ ) , a vali date d measure of cognitive as well as physical symptoms of MDD , before and after treatment . RESULTS There was a greater improvement in the ability to recall information ( p=0.04 ) and a trend toward statistical significance for greater improvement in word-finding ( p=0.09 ) for patients who received adjunctive SAMe than placebo . None of the remaining five items reached statistical significance . CONCLUSION These preliminary data suggest that SAMe can improve memory-related cognitive symptoms in depressed patients , and warrant replication
Results show that various classes of antidepressants exert improving effects on cognitive function across several cognitive domains .
Specifically , studies suggest that SSRIs , the SSRE tianeptine , the SNRI duloxetine , vortioxetine and other antidepressants such as bupropion and moclobemide may exert certain improving effects on cognitive function in depression , such as in learning and memory and executive function .
The few non-pharmacological studies conducted employing cognitive orientated treatments and cognitive remediation therapy show promising results for the improvement of cognitive impairment in depression .
Cognitive dysfunction is of clinical significance and exerts longst and ing implication on patients ׳ function .
Pharmacological and non-pharmacological treatments of cognitive dysfunction are emerging .
This review evaluates pharmacological and non-pharmacological treatments of cognitive impairment primarily in the domains of memory , attention , processing speed and executive function in clinical depression .